Table 2 Clinicopathological characteristics of the high- and low-SAS groups before and after propensity score matching
Characteristics | Before matching, n (%) | P value | After matching, n (%) | P value | ||
|---|---|---|---|---|---|---|
Group H (SAS >6) | Group L (SAS ≤6) | Group H (SAS >6) | Group L (SAS ≤6) | |||
n = 449 | n = 190 | n = 156 | n = 156 | |||
Age | ||||||
Years, IQR | 70 (62−76) | 69 (62−75) | 0.762 | 69 (61−76) | 69 (62−75) | 0.82 |
Gender | ||||||
Female | 189 (68.7%) | 86 (31.3%) | 0.46 | 70 (50.4%) | 69 (49.6%) | 0.909 |
Male | 260 (71.4%) | 104 (28.6%) | 86 (49.7%) | 87 (50.3%) | ||
BMI | ||||||
kg/m2, IQR | 22.4 (20.4−24.4) | 21.8 (19.9−24.2) | 0.167 | 22.3 (20.6−23.9) | 22.0 (19.8−24.3) | 0.453 |
Smoking | ||||||
Yes | 167 (71.1%) | 68 (28.9%) | 0.737 | 54 (48.2%) | 58 (51.8%) | 0.637 |
No | 282 (69.8%) | 122 (30.2%) | 102 (51.0%) | 98 (49.0%) | ||
CCI | ||||||
< 1 | 231 (69.0%) | 104 (31.0%) | 0.447 | 77 (47.2%) | 86 (52.8%) | 0.308 |
≥ 1 | 218 (71.7%) | 86 (28.3%) | 79 (53.0%) | 70 (47.0%) | ||
Albumin | ||||||
g/dL | 4.1 (3.8−4.3) | 4.0 (3.7−4.3) | 0.003 | 4.1 (3.7−4.3) | 4.1 (3.8−4.3) | 0.985 |
CRP | ||||||
mg/dL | 0.08 (0.03−0.29) | 0.16 (0.05−0.61) | <0.001 | 0.09 (0.03−0.5) | 0.14 (0.04−0.36) | 0.18 |
GPS | ||||||
0 | 394 (73.5%) | 142 (26.5%) | <0.001 | 132 (50.4%) | 130 (49.6%) | 0.758 |
1,2 | 55 (53.4%) | 48 (46.6%) | 24 (48.0%) | 26 (52.0%) | ||
ASA-PS | ||||||
1 | 71 (70.3%) | 30 (29.7%) | 0.8 | 24 (53.3%) | 21 (46.7%) | 0.862 |
2 | 325 (70.8%) | 134 (29.2%) | 114 (49.1%) | 118 (50.9%) | ||
3 | 53 (67.1%) | 26 (32.9%) | 18 (51.4%) | 17 (48.6%) | ||
Location | ||||||
Colon | 329 (71.5%) | 131 (28.5%) | 0.266 | 111 (49.1%) | 115 (50.9%) | 0.612 |
Rectum | 120 (67.0%) | 59 (33.0%) | 45 (52.3%) | 41 (47.7%) | ||
pT | ||||||
1 | 132 (79.5%) | 34 (20.5%) | 0.003 | 38 (52.8%) | 34 (47.2%) | 0.469 |
2 | 76 (75.2%) | 25 (24.8%) | 23 (53.5%) | 20 (46.5%) | ||
3 | 168 (65.9%) | 87 (38.7%) | 70 (51.5%) | 66 (48.5%) | ||
4 | 73 (62.4%) | 44 (37.6%) | 25 (41.0%) | 36 (59.0%) | ||
pN | ||||||
0 | 326 (72.3%) | 125 (27.7%) | 0.064 | 106 (50.0%) | 106 (50.0%) | 1 |
1 | 89 (69.0%) | 40 (31.0%) | 32 (50.0%) | 32 (50.0%) | ||
2 | 34 (57.6%) | 25 (42.4%) | 18 (50.0%) | 18 (50.0%) | ||
pStage | ||||||
I | 186 (77.8%) | 53 (22.2%) | 0.005 | 55 (52.9%) | 49 (47.1%) | 0.712 |
II | 140 (66.0%) | 72 (34.0%) | 51 (47.2%) | 57 (52.8%) | ||
III | 123 (65.4%) | 65 (34.6%) | 50 (50.0%) | 50 (50.0%) | ||
Histologically tumor type | ||||||
Differentiated | 432 (71.2%) | 175 (28.8%) | 0.03 | 146 (50.0%) | 146 (50.0%) | 1 |
Undifferentiated | 17 (53.1%) | 15 (46.9%) | 10 (50.0%) | 10 (50.0%) | ||
Procedures | ||||||
Laparoscopy | 348 (81.1%) | 81 (18.9%) | <0.001 | 81 (50.0%) | 81 (50.0%) | 1 |
Open surgery | 101 (48.1%) | 109 (51.9%) | 75 (50.0%) | 75 (50.0%) | ||
EBL | ||||||
mL, IQR | 38 (20−80) | 168 (50−410) | <0.001 | 50 (20−100) | 118 (31−286) | <0.001 |
Operative time | ||||||
min, IQR | 211 (175−266) | 234 (176−287) | 0.023 | 213 (178−270) | 226 (170−266) | 0.798 |
Transfusion | ||||||
Yes | 19 (40.4%) | 28 (59.6%) | <0.001 | 8 (34.8%) | 15 (65.2%) | 0.129 |
No | 430 (72.6%) | 162 (27.4%) | 148 (51.2%) | 141 (48.8%) | ||
POC | ||||||
≤ CDC II | 393 (73.2%) | 144 (26.8%) | <0.001 | 135 (52.3%) | 123 (47.7%) | 0.073 |
≥ CDC III | 56 (54.9%) | 46 (45.1%) | 21 (38.9%) | 33 (61.1%) | ||
Postoperative stay | ||||||
Days, IQR | 12 (10−18) | 14 (11−23) | <0.001 | 13 (11−19) | 13 (10−22) | 0.592 |